Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
Go back to Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma| Pfizer Inc. (NYSE: PFE) | Delayed: 27.83 +0.09 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.74 | 52 Week High | $37.39 | |||
| Open | $27.74 | 52 Week Low | $28.25 | |||
| Day High | $28.00 | P/E | 16.87 | |||
| Day Low | $27.49 | EPS | $1.65 | |||
| Volume | 13,482,997 | |||||
